Name: Human SETD7 antibody
Price: 592.00 USD

- Overview
  - Please contact us at for specific academic pricing.
- Properties
  - Host
    
    mouse
    
    Antibody Type
    
    monoclonal
    
    Isotype
    
    IgG2b kappa
    
    Reactivity
    
    human
    
    Clone
    
    s4E5
    
    Immunogen
    
    Recombinant human SET7/9 (1-366aa) purified from E. coli
    
    Purification
    
    By protein-A affinity chromatography
    
    Formulation
    
    Liquid. In Phosphate-Buffered Saline (pH 7.4) with 0.02% Sodium Azide, 10% glycerol
    
    Storage
    
    Can be stored at +2°C to +8°C for 1 week. For long term storage, aliquot and store at -20°C to -80°C. Avoid repeated freezing and thawing cycles.
    
    Concentration
    
    1mg/ml (determined by BCA assay)
    
    Antigen
    
    SETD7, SET7, SET9, SET7/9, SET7/9 Histone methyltransferase, SET domain-containing protein 8, SET domain-containing protein 7 FLJ21193, SET domain-containing protein 7, Lysine N-methyltransferase 7, Lysine methyltransferase, KMT7, KIAA1717, Histone-lysine N-methyltransferase SETD7, Histone-lysine N-methyltransferase, Histone lysine N methyltransferase H3 lysine 4 specific SET7, Histone lysine methyltransferase, Histone H4-K4 methyltransferase, Histone H3-K4 methyltransferase SETD7, Histone H3 lysine 4 specific methyltransferase, Histone H3 K4 methyltransferase, H4 lysine-4 specific, H3-K4-HMTase SETD7, H3 K4 HMTase, EC 2.1.1.43 (UniProt:Q8WTS6)
    
    * For research use only. Not intended for human, diagnostics or veterinary use.
- Applications
  - Application
    
    ELISA; WB; ICC/IF; FACS
    
    Application Description
    
    The antibody has been tested by ELISA, Western blot, ICC/IF and FACS analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results
- Reference
  - Giannios I, et al. Protein Methyltransferase Inhibition Decreases Endocrine Specification Through the Upregulation of Aldh1b1 Expression. (Stem Cells. 2019)
    Si W, et al. SET7/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. (Cell Death Dis. 2020)
    Xie H, et al. METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. (J Cell Mol Med. 2020)
    Cao L, et al. Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway. (Int J Mol Med. 2020)
    Jetton TL, et al. SetD7 (Set7/9) is a novel target of PPARγ that promotes the adaptive pancreatic β-cell glycemic response. (J Biol Chem. 2021)
    Li X, et al. Associating Preoperative MRI Features and Gene Expression Signatures of Early-stage Hepatocellular Carcinoma Patients using Machine Learning. (J Clin Transl Hepatol. 2022)
    Li J, et al. ZKSCAN5 Activates VEGFC Expression by Recruiting SETD7 to Promote the Lymphangiogenesis, Tumour Growth, and Metastasis of Breast Cancer. (Front Oncol. 2022)

ICC/IF analysis of SET7/9 in HeLa cells. The cell was stained with ATGA0524 (1:100). The secondary antibody (green) was used Alexa Fluor 488.

Human SETD7 antibody

Human SETD7 antibody

We Also Recommend

Human AK3 antibody

Human Snail antibody

Human STAT1 antibody